Please ensure Javascript is enabled for purposes of website accessibility

FDA to Review Merck's New HPV Vaccine

By Brian Orelli, PhD – Feb 20, 2014 at 3:18PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Merck's V503 protects against more HPV types than Merck's Gardasil or GlaxoSmithKline's Cervarix.

Merck (MRK 0.88%) announced today that the Food and Drug Administration has accepted a marketing application for V503, its new vaccine against human papillomavirus, or HPV.

The pharmaceutical giant currently sells Gardasil, which protects against four types of HPV. GlaxoSmithKline (GSK -0.68%) also sells an HPV vaccine, Cervarix, but it only guards against two types of HPV. 

Covering more types of the virus has helped sales. Last year, Merck sold $1.8 billion worth of Gardasil worldwide. Sales of Cervarix by GlaxoSmithKline were only $270 million. 

V503 is designed to protect against nine different types of the virus. In a clinical trial presented at the European Research Organisation on Genital Infection and Neoplasia, V503 protected against 97% of the pre-cancers caused by the five additional viruses that V503 covers. For the four types of HPV that are covered by both V503 and Gardasil, the two vaccines produced equivalent levels of antibodies to the viruses, suggesting V503 works just as well for those virus types.

The increased coverage may not result in increased prescriptions since the CDC already recommends that all preteens get the current vaccines, but V503 could take some additional sales from GalxoSmithKline. Merck may also be able to justify a price increase over Gardasil because of the decrease in potential cancers.

V503 will receive a standard review, so Merck should receive an approval decision within a year of when the company submitted its application to the agency.

link

Brian Orelli has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Merck & Co. Stock Quote
Merck & Co.
MRK
$108.45 (0.88%) $0.95
GSK plc Stock Quote
GSK plc
GSK
$33.76 (-0.68%) $0.23

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
356%
 
S&P 500 Returns
118%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 11/29/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.